Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CELC
Upturn stock ratingUpturn stock rating

Celcuity LLC (CELC)

Upturn stock ratingUpturn stock rating
$13.35
Last Close (24-hour delay)
Profit since last BUY11.81%
upturn advisory
Consider higher Upturn Star rating
BUY since 19 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CELC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $28.5

1 Year Target Price $28.5

Analysts Price Target For last 52 week
$28.5Target price
Low$7.58
Current$13.35
high$19.77

Analysis of Past Performance

Type Stock
Historic Profit -8.82%
Avg. Invested days 36
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 474.84M USD
Price to earnings Ratio -
1Y Target Price 28.5
Price to earnings Ratio -
1Y Target Price 28.5
Volume (30-day avg) 7
Beta 0.39
52 Weeks Range 7.58 - 19.77
Updated Date 06/30/2025
52 Weeks Range 7.58 - 19.77
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.05

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -39.04%
Return on Equity (TTM) -115.39%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 366726138
Price to Sales(TTM) -
Enterprise Value 366726138
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -7.8
Shares Outstanding 37866400
Shares Floating 20785601
Shares Outstanding 37866400
Shares Floating 20785601
Percent Insiders 13.21
Percent Institutions 82.08

Analyst Ratings

Rating 3
Target Price 28.5
Buy 2
Strong Buy 5
Buy 2
Strong Buy 5
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Celcuity LLC

stock logo

Company Overview

overview logo History and Background

Celcuity LLC is a precision oncology company pursuing uniquely positioned targeted therapies to drive new hope for patients with cancer. It was founded with the goal of identifying cancer patients likely to benefit from specific therapies.

business area logo Core Business Areas

  • Drug Development: Focuses on developing targeted therapies for specific cancer subtypes based on their CELsignia diagnostic platform.
  • Diagnostic Services: Offers the CELsignia diagnostic platform to pharmaceutical companies and researchers to identify patient populations most likely to respond to targeted therapies in clinical trials.

leadership logo Leadership and Structure

Brian Sullivan serves as the Chief Executive Officer. The company has a board of directors and a management team responsible for strategic direction and operations.

Top Products and Market Share

overview logo Key Offerings

  • Gedatolisib: Gedatolisib is an investigational PI3K/mTOR inhibitor currently in clinical development for HR+/HER2- advanced or metastatic breast cancer. No market share data is currently available as it's still in clinical trials. Competitors include other PI3K inhibitors such as those from Novartis and Bayer, as well as standard-of-care hormonal therapies.
  • CELsignia Diagnostic Platform: A diagnostic platform used to identify which cancer patients are most likely to respond to specific targeted therapies. Revenue derived from pharmaceutical partnerships utilizing the platform. Competitors include other diagnostic companies offering similar profiling services, such as Foundation Medicine (FMI).

Market Dynamics

industry overview logo Industry Overview

The precision oncology industry is rapidly growing, driven by advancements in genomic sequencing and targeted therapies. The market is competitive, with numerous companies developing diagnostic tools and targeted treatments.

Positioning

Celcuity is positioned as a precision oncology company focused on identifying patient populations most likely to respond to targeted therapies, differentiating itself through its CELsignia diagnostic platform and targeted drug development program.

Total Addressable Market (TAM)

The TAM for precision oncology is estimated to be in the billions of dollars, continually expanding with new discoveries. Celcuity is positioning itself to capture a portion of this TAM by partnering with pharmaceutical companies to apply its diagnostics and developing its own targeted therapies.

Upturn SWOT Analysis

Strengths

  • Proprietary CELsignia diagnostic platform
  • Targeted therapy development approach
  • Partnerships with pharmaceutical companies
  • Strong intellectual property portfolio

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on successful clinical trial outcomes
  • Early stage commercialization

Opportunities

  • Expanding applications of the CELsignia platform to other cancer types
  • Partnering with additional pharmaceutical companies
  • Advancing Gedatolisib through clinical trials and potential regulatory approval
  • Acquisition by a larger pharmaceutical firm

Threats

  • Competition from other diagnostic and pharmaceutical companies
  • Failure of clinical trials
  • Regulatory hurdles
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • FMI
  • DGX
  • QDEL

Competitive Landscape

Celcuity's competitive advantage lies in its CELsignia diagnostic platform's ability to identify specific patient populations, but it faces competition from larger, more established diagnostic and pharmaceutical companies. The stock symbol 'CELC' financials dictate the revenue.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is dependent on successful clinical trials and adoption of its diagnostic platform. Financial data to reflect these is reflected under the stock symbol CELC.

Future Projections: Future growth is dependent on the success of Gedatolisib's clinical trials and commercialization, as well as continued adoption of the CELsignia diagnostic platform.

Recent Initiatives: Focus on advancing Gedatolisib through clinical trials and expanding partnerships for its CELsignia platform.

Summary

Celcuity is a precision oncology company with a promising diagnostic platform and targeted therapy in development. While it faces competition and relies on clinical trial success, its unique approach to identifying patient populations for targeted therapies offers significant potential. The company needs to secure more partnerships and funding to continue its growth. Securing funding to perform tests will enable them to gather the needed diagnostic data to improve targeted therapies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Celcuity LLC company website
  • SEC filings (CELC)
  • Industry reports
  • Analyst reports

Disclaimers:

This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Celcuity LLC

Exchange NASDAQ
Headquaters Minneapolis, MN, United States
IPO Launch date 2017-09-20
Co-Founder, Chairman & CEO Mr. Brian F. Sullivan
Sector Healthcare
Industry Biotechnology
Full time employees 87
Full time employees 87

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.